Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromfenac sodium eye drops for postoperative cataract inflammation and noninfectious ocular surface inflammation
CTR20140528Phase 3Completed
- Sponsor
- Hefei Jiunuo Pharmaceutical Technology
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bromfenac sodium in post-operative inflammation, Ocular surface inflammation, allergic conjunctivitis (AC), giant papillary conjunctivitis (GPC), Drug-induced conjunctivitis, sponsored by Hefei Jiunuo Pharmaceutical Technology. Started Aug 2014; status: completed.
02
Drugs
bromfenac sodium
03
Conditions
post-operative inflammationOcular surface inflammationallergic conjunctivitis (AC)giant papillary conjunctivitis (GPC)Drug-induced conjunctivitis
Beyond the preview
Go deeper on CTR20140528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140528.